State of the science in cervical cancer: where we are today and where we need to go (Q27027042)

Helen J. Mackay

2

1 reference

Gillian M. Thomas

3

1 reference

Theresa L. Werner

4

1 reference

Elise C. Kohn

5

1 reference

Dina Hess

6

1 reference

Peter G. Rose

7

1 reference

Allan L. Covens

8

1 reference

language of work or name

1 reference

1 August 2014

1 reference

1 reference

120

1 reference

PubMed

issue

15

1 reference

PubMed

page(s)

2282-8

1 reference

PubMed

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: prognostic and predictive factors and the impact of disease stage on outcomes from a prospe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Improved survival with bevacizumab in advanced cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Landscape of genomic alterations in cervical carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Host immune responses to cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Immunotherapy for gynaecological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28722

7 January 2021

Identifiers

DOI

10.1002/CNCR.28722

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

24737608

1 reference

Consolidated OpenCitations Corpus – April 2017